RxDoctor Payments Data

Robert Ryan, MD

Urology · Seguin, TXNPI 1780764258

Payments from drug & device makers

$2,480in general payments, 2019–2025

Across 90 payments — averaging $27.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$496
  • Sumitomo Pharma America, Inc.$401
  • Intuitive Surgical$391
  • Urovant Sciences Inc$219
  • Cook Medical LLC$213
  • Pfizer$201
  • plus $560 from 10 others

What the payments were for

  • Food & beverage$2,22590%
  • Education$25510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,480 in reported general payments places this provider in the 35th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$273,794
Medicare patients
781
Services billed
3,480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide18$269,482
MyrbetriqMirabegron260$207,282
GemtesaVibegron167$120,938
OrgovyxRelugolix38$101,171
Mirabegron ErMirabegron38$29,576
ElmironPentosan Polysulfate Sodium11$26,045
Tamsulosin Hcl728$13,759
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst131$6,429
Testosterone Cypionate121$5,527
Silodosin60$4,869
Oxybutynin Chloride ErOxybutynin Chloride186$4,773
Solifenacin Succinate147$3,926
Finasteride214$3,255
Tolterodine Tartrate ErTolterodine Tartrate21$3,214
Estradiol37$2,539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$496$476,764278 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$401$222,110205 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 878 urology providers in Texas.

Other urology in Seguin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →